Memorial Sloan Kettering Cancer Center’s CEO on the Future of Cancer Treatment

MSK Institutional Overview

• Memorial Sloan Kettering (MSK) operates as a specialized $8 billion revenue entity with 22,000 employees, distinct from the average US health system which averages $1–2 billion in diversified revenue.
• The institution generates approximately five major publications in top-tier journals (e.g., Nature, NEJM) monthly, often redefining care paradigms for lymphoma, myeloma, and gastric cancer.
• MSK maintains the world's largest cancer tissue biobank, encompassing fluids, tissue, x-rays, and genomic data, serving as the foundation for its research output.

The "Golden Era" of Cancer Treatment: Key Drivers

• Survival Trends: Cancer survival rates have increased from approximately 40% in the late 1990s to roughly 60% for all comers today.
• Targeted Therapy: Systemic tumor sequencing identifies specific drug targets in 45–47% of patients, enabling precision oncology rather than standard off-the-shelf treatments.
• Immunotherapy Advancements: Cellular therapies like CAR-T have flipped survival outcomes for aggressive liquid tumors (e.g., acute leukemia mortality shifted from 80% to 20% prior to therapy; post-therapy survival rates reversed this).
• Vaccines: A phase trial using mRNA vaccines for pancreatic cancer (BioNTech partnership) increased 5-year survival from the historical 10% baseline to 90% in treated cohorts with minimal residual disease.
• Computational Oncology: The field relies on experts with dual PhDs in abstract mathematics and molecular biology to manage the exponential growth of genomic data, where 90% of healthcare data was generated in the last five years and is projected to double in the next two.

Artificial Intelligence and Predictive Modeling

• Large Language Models (LLMs): Training LLMs on unique MSK data (x-rays, pathology slides, lab values, and outcomes) allows for outcome predictions that surpass current genomic and clinical staging methods.
• Predictive Capabilities: These models can predict tumor recurrence locations and survival probability with higher accuracy than traditional metrics.
• Infrastructure Bottlenecks: Current AI scaling is limited by GPU availability; projects that could theoretically run in two weeks are taking five months due to computing constraints.

Emerging Risks and Prevention Trends

• Rising Youth Incidence: Recent data indicates a 15–20% increase in colorectal cancer incidence among individuals under 40, with a projected 30% rise in the under-50 cohort between 2019 and 2030.
• Etiology Factors: While obesity and microplastics are suspected contributors, no single environmental factor has been definitively isolated as the cause.
• Preventive Behavior: Only 10% of at-risk Americans utilize low-dose CT scans for lung cancer screening, and colonoscopy rates have dropped to 45%.
• Genetic Screening: Tools like "MSK-Choice" allow patients to screen for hereditary cancer risks (2–3% of the population) via mouth swabs, identifying germline mutations in 60–70 known genes.
• Polygenic Risk Scores: Computational methods can now predict cancer and heart attack risks based on gene profiles rather than single-gene signals, offering superior accuracy to traditional markers like PSA.

Clinical Breakthroughs in Specific Cancers

• Gliomas: Targeted drugs (e.g., IDH inhibitors) in glioma trials halted early due to efficacy, increasing survival capacity by up to 60%.
• Colorectal Cancer (Mismatch Repair Deficiency): 100% cure rate achieved in 117 patients with mismatch repair-deficient tumors using checkpoint blockade immunotherapy, eliminating the need for surgery, radiation, or chemotherapy for this subgroup (5–7% of colon cancer cases).
• Pancreatic Cancer: While surgical mortality has dropped from 25% to <2%, only 10–12% of patients are eligible for surgery; vaccines are now targeting neo-antigens to address minimal residual disease post-surgery.
• Global Application: The immunotherapy protocol for mismatch repair-deficient colorectal cancer is being deployed in Nigeria, where 30% of cases share this genetic defect, offering a low-infrastructure cure option.

Health Equity and Social Determinants

• Geospatial Epigenomics: A new research initiative led by the Jeffrey Canada Center investigates how location ("zip code") and environmental stress modify tumor aggressiveness, potentially making race less relevant than neighborhood conditions.
• Outcome Disparities: Black men consistently demonstrate the lowest life expectancy and worst outcomes across all cancer types, driven largely by social determinants of health.
• Economic Model: The US healthcare reimbursement structure incentivizes disease treatment over prevention, creating a barrier to widespread screening adoption despite evidence that early detection (e.g., low-dose CT) improves survival.
• Access Barriers: Approximately 80% of patients needing CAR-T therapy cannot access it due to cost, highlighting a significant disparity in utilizing curative technologies.

Personal and Historical Context

• Founder Background: Dr. Selwyn Vickers was born in the Black Belt of Alabama, the first African-American surgeon on the faculty at the University of Alabama at Birmingham, and the first to perform a major liver resection on a patient there.
• Mentorship Philosophy: He cites a principle taught by a Johns Hopkins dean: "There is always room at the top," emphasizing that exceptional performance ensures professional opportunity regardless of market saturation.
• Civil Rights Legacy: His parents lost their jobs twice for participating in civil rights rallies, reinforcing a family history of using education and professional excellence to fight systemic barriers.